Atlas Trials

Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

Clinical trial NCT03021057 · UNKNOWN

Trial details

NCT number
NCT03021057
Sponsor
The University of Hong Kong
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
T-Cell LymphomaNK-Cell Lymphoma
Start date
2016-12-01
Primary completion
2020-06-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.